Catalent
CTLT
#1566
Rank
A$17.35 B
Marketcap
$95.59
Share price
0.75%
Change (1 day)
59.45%
Change (1 year)
Catalent is an American pharmaceutical contract research and development company.

P/E ratio for Catalent (CTLT)

P/E ratio as of December 2024 (TTM): -47.6

According to Catalent's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -47.6202. At the end of 2022 the company had a P/E ratio of 19.8.

P/E ratio history for Catalent from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202219.8-49.36%
202139.2-31.53%
202057.2-13.67%
201966.2112.43%
201831.2-56.74%
201772.197.82%
201636.4166.37%
201513.7-76.5%
201458.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
47.2-199.18%๐Ÿ‡บ๐Ÿ‡ธ USA
-20.3-57.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-86.2 81.07%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
2.97-106.24%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.